Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics

Although NIST has now published the data needed to generate match statistics for NGS-based profiles, other hurdles must still be cleared before the new technology sees widespread use in forensics. For instance, labs will have to develop ways to manage the greater amounts of data produced by NGS. They will also have to implement operating procedures and quality controls for the new technology. Still, while much work remains, said Peter Vallone, the research chemist who leads NIST’s forensic genetics research, “We’re laying the foundation for the future.”

DNA is often considered the most reliable form of forensic evidence, and this reputation is based on the way DNA experts use statistics. When they compare the DNA left at a crime scene with the DNA of a suspect, experts generate statistics that describe how closely those DNA samples match. A jury can then take those match statistics into account when deciding guilt or innocence.

These match statistics are reliable because they’re based on rigorous scientific research. However, that research only applies to DNA fingerprints, also called DNA profiles, that have been generated using current technology. Now, scientists at the National Institute of Standards and Technology (NIST) have laid the statistical foundation for calculating match statistics when using Next Generation Sequencing, or NGS, which produces DNA profiles that can be more useful in solving some crimes. This research, which was jointly funded by NIST and the FBI, was published in Forensic Science International: Genetics.

“If you’re working criminal cases, you need to be able to generate match statistics,” said Katherine Gettings, the NIST biologist who led the study. “The data we’ve published will make it possible for labs that use NGS to generate those statistics.”

Read more

Alphabet, Inc., the parent company of Google, plans to develop a life-long gene therapy for heart disease, the leading cause of death for men and women in the U.S.

Attaining this lofty goal will be the job of Alphabet’s gene-editing start-up, Verve Therapeutics, and Google’s life science start-up, Verily.

This month, Google’s venture fund, GV, partnered with three other funds to launch Verve Therapeutics with $58.5 million in Series A funding. The company’s scientific founders include Dr. Sekar Kathiresan (CEO), Dr. Kiran Musunuru (chief scientific adviser) and Dr. J. Keith Joung (strategic adviser).

Read more

We may like to think that what we do in our daily lives only affects ourselves and perhaps a few people around us, but the increasingly active field of scientific inquiry called epigenetics suggests that life experiences like what we eat and the environments we expose ourselves to can influence the health and development of our kids and the generations beyond them.

Studies of both humans and animals have suggested that a father’s experiences can be transmitted across generations, but the mechanism for this epigentic inheritance hasn’t quite been clear.

New research published Wednesday in Nature Communications details how Susan Strome’s lab at UC Santa Cruz observed the transmission of epigenetic markers in the sperm of the small roundworm Caenorhabditis elegans.

Read more

LMAO The babies died of the flu Keep making mistakes on the aleal borders and the organism dies of viral infections… This seems to be exactly the same result as a majority of the cloned animals over the last thirty years too. It is hard to get that puppy of your favorite dog to stick… Pitty really for the genetically engineered children who will mostly suffer and die before adulthood.

Gene targeted in the ‘CRISPR baby’ scandal might prove fatal, study finds. Nick carne reports.

Read more

Greg Dore at the Kirby Institute of NSW participated in Australia’s Hepatitis C pricing discussions, and believes our model will work for the new gene therapy drugs – notwithstanding their eye-popping price tags – and the fact that the patient populations for these rare genetic diseases will be tiny.

However, the real reason companies are getting into gene therapy is not just to treat rare disease. It’s because they realise this technology will be a game changer for medicine.

Read more

A team of researchers affiliated with the Broad Institute of MIT and Harvard, MIT and the National Institutes of Health has found that CRISPR-associated transposons can be used to insert custom genes into DNA without cutting it. In their paper published in the journal Science, the group describes their new gene-editing technique and how well it worked when tested in a bacterial genome.

The CRISPR gene editing has made headlines in recent years due to its potential for treating hereditary diseases. Unfortunately, despite much research surrounding the technique, it is still not a viable option for use on human patients. This is because the technique is error-prone—when snipping strands of DNA, CRISPR sometimes cuts off-target DNA as well, leading to unintended and unpredictable consequences (and sometimes cancerous tumors). In this new effort, the researchers have found a way to use CRISPR in conjunction with another protein to edit a strand of DNA without cutting it—they are calling it CRISPR-associated transposase (CAST).

Prior research has shown that certain pieces of DNA called transposons are, for unknown reasons, able to reposition themselves in a genome spontaneously—for this reason, they have come to be known as jumping genes. Not long after they were discovered, researchers noted that they might be used for gene editing. This is what the researchers did in the new study. They associated a transposon called Tn7 with the Cas12 enzyme used with CRISPR to edit a section of a bacterial genome. In practice, CRISPR led the Tn7 transposon to the target location in the genome—at that point, the transposon inserted itself into the without cutting it.

Read more

UMBC postdoctoral fellow Sarah Stellwagen and co-author Rebecca Renberg at the Army Research Lab have published the first-ever complete sequences of two genes that allow spiders to produce glue—a sticky, modified version of spider silk that keeps a spider’s prey stuck in its web. The findings appeared in Genes, Genomes, Genetics.

The innovative method they employed could pave the way for others to sequence more silk and glue , which are challenging to sequence because of their length and repetitive structure. Better understanding of these genes could move scientists closer to the next big advance in biomaterials.

Read more

Researchers at Amsterdam’s UMC have identified a rare gene that halves people’s chances of developing dementia in old age.

People with the genetic variant, which occurs in around 1% of the population, are also more likely to live longer. The researchers studied 16 different sample populations in Europe and North America, including a number of people over the age of 100, for the study published in the journal Acta Neuropathologica.

The discovery could potentially be used to treat Alzheimer’s disease and other degenerative illnesses such as frontotemporal and Lewy body dementia.

Read more

David A. Sinclair, Ph.D., A.O. is an Australian biologist and a Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School. He is best known for his work on understanding why we age and how to slow its effects. He obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney, and received the Australian Commonwealth Prize. In 1995, he received a Ph.D. in Molecular Genetics then worked as a postdoctoral researcher at the Massachusetts Institute of Technology with Leonard Guarente. Since 1999 he has been a tenured professor in the Genetics Department of Harvard Medical School.

Dr. Sinclair is co-founder of several biotechnology companies (Sirtris, Ovascience, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others. He is also co-founder and co-chief editor of the journal Aging. His work is featured in five books, two documentary movies, 60 Minutes, Morgan Freeman’s “Through the Wormhole” and other media.

Read more